Serum dextromethorphan/dextrorphan metabolic ratio for CYP2D6 phenotyping in clinical practice

Journal of Clinical Pharmacy and Therapeutics

Volumn 37, Issue 4, 2012, Pages 486-490

  Jurica, J ^a   Bartecek, R ^a   Zourkova, A ^a   Pindurova, E ^b   Sulcova, A ^a   Kasparek, T ^a   Zendulka, O ^a  

^a MASARYK UNIVERSITY   (Czech Republic)

^b UNIVERSITY HOSPITAL BRNO   (Czech Republic)

Author keywords

CYP2D6; dextromethorphan; genotype; metabolic ratio; phenotype; serum

Indexed keywords

CYTOCHROME P450 2D6; DEXTROMETHORPHAN; DEXTRORPHAN; GUAIFENESIN;

ADULT; AGED; ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG URINE LEVEL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHARMACOGENETICS; PHENOTYPE;

ADOLESCENT; ADULT; AGED; CASE-CONTROL STUDIES; CYTOCHROME P-450 CYP2D6; DEXTROMETHORPHAN; DEXTRORPHAN; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PHENOTYPE; ROC CURVE; YOUNG ADULT;

EID: 84863437931     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2012.01333.x     Document Type: Article

References (23)

1. The Human Cytochrome P450 (CYP) Allele Nomenclature Database. Available at: http://www.cypalleles.ki.se/ (accessed 17 August 2011).
2. Zanger UM, Raimundo S, Eichelbaum M,. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol, 2004; 369: 23-37. (Pubitemid 38161221)
3. Stearns V, Johnson MD, Rae JM, et al. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst, 2003; 95: 1758-1764. (Pubitemid 38008898)
4. Corruble E,. Non-response to consecutive antidepressant therapy caused by CYP2D6 ultrarapid metabolizer phenotype. Int J Neuropsychopharmacol, 2008; 11: 727-728. (Pubitemid 351931827)
5. Fleeman N, Dundar Y, Dickson R, et al. Cytochrome P450 testing for prescribing antipsychotics in adults with schizophrenia: systematic review and meta-analyses. Pharmacogenomics J, 2011; 11: 1-14.
6. Zhou SF,. Polymorphism of human cytochrome P450 2D6 and its clinical significance Part I. Clin Pharmacokinet, 2009; 48: 689-723.
7. Chladek J, Zimova G, Beranek M, Martinkova J,. In-vivo indices of CYP2D6 activity: comparison of dextromethorphan metabolic ratios in 4-h urine and 3-h plasma. Eur J Clin Pharmacol, 2000; 56: 651-657. (Pubitemid 32204484)
8. Lotsch J, Rohrbacher M, Schmidt H, et al. Can extremely low or high morphine formation from codeine be predicted prior to therapy initiation? Pain, 2009; 144: 119-124.
9. Ito T, Kato M, Chiba K, Okazaki O, Sugiyama Y,. Estimation of the interindividual variability of cytochrome 2D6 activity from urinary metabolic ratios in the literature. Drug Metab Pharmacokinet, 2010; 25: 243-253.
10. Hu OYP, Tang HS, Lane HY, Chang WH, Hu TM,. Novel single-point plasma or saliva dextromethorphan method for determining CYP2D6 activity. J Pharmacol Exp Ther, 1998; 285: 955-960.
11. Shiran MR, Chowdry J, Rostami-Hodjegan A, et al. A discordance between cytochrome P450 2D6 genotype and phenotype in patients undergoing methadone maintenance treatment. Br J Clin Pharmacol, 2003; 56: 220-224. (Pubitemid 36981438)
12. Kohler D, Hartter S, Fuchs K, Sieghart W, Hiemke C,. CYP2D6 genotype and phenotyping by determination of dextromethorphan and metabolites in serum of healthy controls and of patients under psychotropic medication. Pharmacogenetics, 1997; 7: 453-461. (Pubitemid 27517573)
13. Sachse C, Brockmoller J, Bauer S, Roots I,. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet, 1997; 60: 284-295. (Pubitemid 27058401)
14. Stamer UM, Bayerer B, Wolf S, Hoeft A, Stuber F,. Rapid and reliable method for cytochrome P450 2D6 genotyping. Clin Chem, 2002; 48: 1412-1417. (Pubitemid 34925775)
15. Daly AK, Steward A,. Use of the expand™ long template PCR system in genotyping for polymorphisms in the human cytochrome P450 CYP2D6 gene. Biochemica, 1997; 4: 31-32.
16. Zimova G, Chladek J, Martinkova J, Beranek M,. HPLC determination of dextromethorphan and its metabolites in urine. Chemicke Listy, 2000; 94: 132-135.
17. Bailey B, Daneman R, Daneman N, Mayer JM, Koren G,. Discrepancy between CYP2D6 phenotype and genotype derived from post-mortem dextromethorphan blood level. Forensic Sci Int, 2000; 110: 61-70. (Pubitemid 30232771)
18. Daly AK, Leathart JBS, London SJ, et al. CYP2D6 phenotype-genotype relationships in African-Americans and Caucasians in Los Angeles. Pharmacogenetics, 1998; 8: 529-541. (Pubitemid 29043386)
19. Yeh GC, Tao PL, Ho HO, et al. Analysis of pharmacokinetic parameters for assessment of dextromethorphan metabolic phenotypes. J Biomed Sci, 2003; 10: 552-564.
20. Frank D, Jaehde U, Fuhr U,. Evaluation of probe drugs and pharmacokinetic metrics for CYP2D6 phenotyping. Eur J Clin Pharmacol, 2007; 63: 321-333. (Pubitemid 46399125)
21. Gaedigk A, Simon SD, Pearce RE, et al. The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin Pharmacol Ther, 2008; 83: 234-242.
22. Ducharme J, Abdullah S, Wainer IW,. Dextromethorphan as an in vivo probe for the simultaneous determination of CYP2D6 and CYP3A activity. J Chromatogr B Biomed Appl, 1996; 678: 113-128. (Pubitemid 26114747)
23. Ingelman-Sundberg M,. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J, 2005; 5: 6-13. (Pubitemid 40220611)